Cannabis Chutzpah: United Nation’s Anti-Drug Agency Is Dopey

Talk about chutzpah! The United Nation’s Anti-drug agency, International Narcotic Control Board, recently attacked the Parliament-sanctioned Canadian Medical Cannabis Program, oddly looking right past Prohibition-addled but medical cannabis-friendly America.

That’s right.

Despite the continued 73-year old federal prohibition against cannabis, with 90 million Americans currently living in 14 states and the District of Columbia that have legal protections for medical patients who use cannabis with a physician’s recommendation (and 120 million living in states where cannabis possession is decriminalized), 2,000 or more retail outlets or delivery services for medical cannabis (including 24/7 medical cannabis vending machines in California) and a federally subsidized cannabis farm that, among other projects, supplies five medical cannabis patients 300 pre-rolled ‘joints’ per month (which equates to about ten ounces per month!) for the rest of their lives in a closed, grandfathered program, the United Nation’s anti-drug agency ridiculously believes the world urgently needs to take great heed in the Canadian government’s eight-year old and largely uncontroversial medical cannabis program.

Why? Why does the United Nation’s anti-drug agency believe now is a good time to stick its unwanted nose in the national and local concerns of citizens–from The Netherlands to America to Canada to Mexico–who no longer support cannabis prohibition, most notably for medical purposes?

Cannabis policy reform advocates have been readily vexed by the United Nation’s extreme anti-cannabis advocacy and propaganda since the 1970s, and arguably after America’s original drug czar Harry J. Anslinger, in his last act as a life-long anti-cannabis zealot and 30-year plus federal drug czar, he watched President John F. Kennedy commit the world and then American-dominated United Nations to America’s Reefer Madness via the signing of the Single Convention Treaty in 1961.

Why would the United Nation’s attack Canada’s fairly limited medical cannabis program, where the federal government tightly controls production and distribution, yet some how not cast the same critical eye towards cannabis-tolerant America (and the near narco-state of Mexico to the south where the fields of cannabis are viewed by satellite and the federal government recently decriminalized small amounts of drugs)?

If Canada is getting grief from the blue helmet crowd, shouldn’t the governors of New Mexico, New Jersey, Rhode Island and Maine be receiving the same as their states sanction medical cannabis distribution?

One year after George Bush 2.0 left the White House, and with the general support and guidance provided by the Obama administration to move in a direction of greater governmental acceptance of medical cannabis, it seems unlikely that the US government is creating the institutional impetus that is encouraging the United Nations to sound like the ghost of Anslinger.

What is the source of Reefer Madness at the United Nations?

UN watchdog takes aim at Canada’s medical marijuana program

By Steven Edwards, Canwest News Service February 24, 2010

UNITED NATIONS — Justice Minister Robert Nicholson said Wednesday the government’s medical marijuana regulations are under review after the UN’s drugs watchdog warned Canada needs to tighten up the system.

The Vienna-based International Narcotics Control Board said Canada is operating outside international treaty rules aimed at minimizing the risk criminals will get hold of cannabis grown under the program.

“The whole question of medical marijuana is being looked at by the minister of health with respect to the options that she has,” said Nicholson, whose ministry serves as the umbrella agency for the government’s anti-drug efforts.

The warning in the INCB’s annual report accompanies praise for the government’s National Anti-Drug Strategy, which the board said it notes “with appreciation.”

Nicholson said he took heart from that, adding it “plays very well” into the government’s efforts to push through a crime bill containing tougher drugs-offences sentencing provisions that has been held up in the Senate.

Public Safety Minister Vic Toews also argued the report “provides further proof that Canada is recognized internationally as a leader in crime prevention.”

Canada increased the number of cannabis cultivation licences a person can hold last year after court decisions stated patients’ earlier access had been too restricted.

Currently, Health Canada has issued almost 4,900 permits allowing people to possess medical marijuana they get from more than 1,100 licensed growers, some of whom are growing it for their own use.

“Canada continues to be one of the few countries in the world that allows cannabis to be prescribed by doctors to patients with certain serious illnesses,” said the INCB report.

But the 1961 Single Convention on Narcotics, which Canada has signed, says the government must be the sole distributor of the otherwise illegal substance, which patients use as a pain reliever.

The opportunity for misuse of the system is reflected in an RCMP review identifying 40 cases in which licensed growers were also trafficking marijuana for profit. The same review found violations in a total of 70 cases.

While the INCB report noted that Canada “intends to reassess” its access-to-cannabis program, it said the board “requests the government to respect the provisions” of the 1961 convention in conducting its review.

The sole company among the growers that Health Canada has contracted to supply some 28 per cent of the current permit holders signalled Wednesday it would welcome a more focused oversight.

“We get severe criticism from the armchair critics and those who feel threatened that we’re infringing on their rights to produce cannabis,” said Brent Zettl, president of Prairie Plant Systems Inc., of Saskatoon.

“But we’re already essentially conforming to the convention.”

Health Canada frequently inspects the company’s operations, and officially “owns” the cannabis it produces for shipment to clients.

Even some involved in helping patients acquire the possession permits agree that the current system is flawed.

“To Health Canada’s self-admittance, there are a lot of grey areas,” said Chad Clelland, director of online and community relations with medicalmarihuana.ca, an Internet-based support site. “But they are so slow to change.”

Still, Clelland said he does not believe that centralized government-run production is the answer.

Why Growing Numbers of Baby Boomers and the Elderly Are Smoking Pot

An excellent and thoughtful analysis appears today via Alternet.org. Below is an excerpt. To read the entire story, please visit here.

Why Growing Numbers of Baby Boomers and the Elderly Are Smoking Pot
More and more of the nation’s 78 million Boomers are discovering they’d rather smoke marijuana than reach for a pharmaceutical

Conventional wisdom dictates that as younger generations slowly replace the old, conservative social traditions are jettisoned. This may be true for issues such as gay marriage, where there are clear divisions among younger and older voters, but when it comes to marijuana reform, the evidence indicates that simplistic divisions of opinion along age lines don’t apply for pot.

Earlier this week, an AP wire article picked up a lot of buzz in the news-cycle, with a title and premise meant to shock the mainstream: “Marijuana Use by Seniors Goes up as Boomers Age.”

The AP article was pegged to a December report released by the Federal Substance Abuse and Mental Health Services Administration (SAMHSA). It revealed that the number of Americans over 50 who had reported consuming cannabis in the year prior to the study had gone up from 1.9 percent to 2.9 percent in the period from 2002 to 2008.

This is supported by earlier polling results. In February 2009, a Zogby poll found that voters aged 50 to 64 were almost equally divided in their support for marijuana legalization at 48 percent. In that same poll, young voters aged 18 to 29 were the cohort who most enthusiastically supported legalization, at 55 percent. But overall support among all ages came in at 44 percent.

So who brought the average down? Don’t lay the blame on the elderly. In fact, as early as 2004, an AARP poll found that 72 percent of its members (all 50-plus, with the lion’s share over 65) supported marijuana for medical purposes, indicating their understanding of the benefits of legal cannabis availability.

Some expert observers in the marijuana reform movement believe that the bulk of marijuana detractors are made up of 30- and 40-somethings — adults of parenting age. And as more of the 65-and-over crowd is populated by Baby Boomers, it appears that in the not-too-distant future every age demographic including the elderly will approve of marijuana reform more than Americans in their 30s and 40s.

Read the rest of the story online here.

NORML’s Weekly Legislative Update

Lawmakers around the country are debating a record number of marijuana law reform bills in 2010. NORML’s Weekly Legislative Round Up is your one-stop guide to pending marijuana law reform legislation around the country, along with tips for influencing the policies of your state.

** A note to first time readers: NORML can not introduce legislation in your state. Nor can any other non-profit advocacy organization. Only your state representatives, or in some cases an individual constituent (by way of their representative; this is known as introducing legislation ‘by request’) can do so. NORML can — and does — work closely with like-minded politicians and citizens to reform marijuana laws, and lobbies on behalf of these efforts. But ultimately the most effective way — and the only way — to successfully achieve statewide marijuana law reform is for local stakeholders and citizens to become involved in the political process and make the changes they want to see. We can’t do it without you.

Massachusetts: On Tuesday, March 2, members of the Joint Committee on the Judiciary will hear testimony in favor of Senate Bill 1801, which seeks to legally regulate the commercial production and distribution of marijuana for adults over 21 years of age. The hearing is scheduled for 1:00pm in room A-1 of the Massachusetts State House. You can read NORML’s written testimony to the Committee here. You can also watch video of NORML representatives previously testifying in favor of this measure before lawmakers here. For information on attending next week’s hearing please visit here, or to contact the Committee, please go here.

Washington, DC: Members of the DC City Council’s Committee on Health this week held their first hearing on implementing the District’s new medical marijuana law. Council members heard several hours of testimony regarding B 18-622, the Legalization of Marijuana for Medical Treatment Initiative Amendment Act 0f 2010, which seeks to implement local regulations regarding the medical use and distribution of medical marijuana to qualified patients. Representatives from NORML testified on behalf of the measure, which is expected to be enacted by the Council by May of this year. If approved by the Council, Congress has 30 days to either approve or reject the measure. More information about this measure is available from NORML’s ‘Take Action Center’ here.

South Dakota: Representatives of the South Dakota Coalition for Compassion this week turned in nearly twice the required number of signatures necessary to place a medical marijuana legalization initiative on the November 2010 statewide ballot. You can read the text of the measure here, or become involved in the campaign by going here. NORML will begin reporting more in depth about this effort once the measure has been certified by the state to appear on the 2010 ballot.

Hawaii: Members of the Senate Committee on Judiciary and Government Operations heard testimony today in favor of SB 2450, which seeks to reduce minor marijuana possession penalties from a criminal misdemeanor, punishable by up to 30 days in jail and a $1000 fine, to a civil infraction punishable by a fine only. You can read NORML’s written testimony in support of the measure, which is co-sponsored by 19 of Hawaii’s 25 Senators, here.

Maryland: On Friday, February 26, at 1:00pm the House Committee of Health and Government Operations and the House Committee of the Judiciary will jointly hear testimony regarding several legislative proposals that seek to legalize the use, production, and distribution of medical marijuana. NORML representatives will be in attendance and testifying at tomorrow’s hearing.

New York: On Tuesday, members of the Senate Health Committee passed S. 4041, which seeks to allow state-qualified patients to possess up to 2.5 ounces of medical marijuana for therapeutic purposes. To learn more about S. 4041 and/or its Assembly companion bill, please visit NORML’s ‘Take Action Center’ here.

For information on additional state and federal marijuana law reform legislation, please visit NORML’s ‘Take Action Center’ here.

Over 2,500 Subjects Since 2005 Have Used Marijuana-Based Medicines In Controlled Clinical Trials

[Editor's note: This post is excerpted from this week's forthcoming NORML weekly media advisory. To have NORML's media advisories delivered straight to your in-box, sign up for NORML's free e-zine here.]

Researchers worldwide have performed 37 separate clinical trials assessing the therapeutic safety and efficacy of inhaled cannabis and marijuana-based medicines since 2005, according to a review published online last week in the journal Cannabinoids: The Journal of the International Association for Cannabinoid Medicines (IACM).

Investigators from Leiden University in the Netherlands and the nova-Institut in Germany conducted a systematic review of recent clinical trial data pertaining to the medical use of whole smoked marijuana and cannabinoids.

Authors identified 37 controlled studies since 2005 evaluating the therapeutic effects of cannabinoids. The trials involved a total of 2,563 subjects.

Of the 37 clinical trials that have been recently conducted, eleven assessed the drug’s impact on chronic neuropathic pain – a difficult to treat type of pain resulting from nerve damage. Other studies assessed the efficacy of cannabinoids to treat multiple sclerosis-associated spasticity (nine separate studies); HIV/AIDS (four); experimental pain (four); intestinal dysfunction (two); nausea/vomiting/appetite (two); schizophrenia (two); glaucoma (one); and ‘other indications (two).

Authors concluded, “Based on the clinical results, cannabinoids present an interesting therapeutic potential mainly as analgesics in chronic neuropathic pain, appetite stimulants in debilitating diseases (cancer and AIDS), as well as in the treatment of multiple sclerosis.”

Last Wednesday investigators from the California Center for Medicinal Cannabis Research released the results of a series of double-blind, placebo-controlled trials that determined that cannabinoids could be “a first-line treatment” for patients suffering from neuropathy.

Commenting on the review, NORML Deputy Director Paul Armentano said: “The safety and efficacy of marijuana as a medicine has now been established by the ‘gold standard’ of clinical study. Further, over 2,500 patients have used cannabinoids in controlled clinical trials over the past five years alone. This is a far greater total than the number of subjects that would likely be administered any other new drug pending United States FDA approval, and is a large enough population to once and for all establish marijuana’s objective value as a medicine.”

Nature’s (Legal) Cannabinoids

“Where Do You Get ‘It’ From?”

Author: Publius*

Most patients don’t get asked where they get their medicine. That’s because everyone knows people get their medicine from a pharmacy. But I have to get my medicine otherwise. I have to safeguard my “source” because my medicine is cannabinoid based – and that makes it almost illegal.  – But not today.  Today I can answer the source question openly because it is my local pharmacy – with drive-thru service and open to dispense medicine 24 hours a day. I drive up and push a big, yellow smiley-faced button to gain access – a soft automated voice comes over the speaker to verify that I am in the right place in order to pick up my prescription. Next, the typical professional looking person – white coat with badge – slides open the window asking my name and what I need.

“I’m picking up a prescription for Publius.”

They return with a baggie and bottle containing 30 synthetic cannabinoid capsules dosed at 5mg each – that’s right, legal cannabinoids!

What are cannabinoids? Well, here is where things get interesting. As one learns in biology, the human body has many systems – the circulatory, respiratory, digestive, and nervous systems to name a few. Each system has parts: for example, the nervous system is made up of the brain, spinal cord, and nerves. By the late 1980s, science identified a new human system – the endocannabinoid system (ECS) – also referred to as the cannabinoid system. There is a cannabinoid system present in all mammals – to include humans and 15,000 other species.  A mammal is any vertebrate animal distinguished by self-regulating body temperature, hair, and milk-producing females – as mammal means “breast” or of the breast.

The ECS has two main parts: cannabinoids, which are chemical neurotransmitters, and two receptors called “CB1″ and “CB2.” Cannabinoids activate receptors found throughout the body – in all organs, for example. In fact, all systems in our bodies are modulated by the cannabinoid system. This means that as a body system changes, it uses the ECS to do so.

Science and popular search sites like Wikipedia use three classifications of cannabinoids:

1.  Endogenous cannabinoids (also referred to as endocannabinoids), which are produced by the human body

2.  Herbal cannabinoids, the kind found in the cannabis sativa plant

3.  Synthetic cannabinoids, produced and distributed by pharmaceutical companies

The third kind is what I am picking up from the pharmacy – 30 Marinol (Dronabinol) capsules. Marinol is a prescribed cannabinoid from my doctor – and I am going to test it against the herbal cannabinoids I have been baking into my brownies for five years now.

The pharmacist hands me a white paper bag containing the Marinol prescribed for my Multiple Sclerosis (MS). Stapled to the top is a typical handout with cautionary medical information. The small amount (150mg) of the synthetic cannabinoid THC costs $370 – or more than $69,000 per ounce!

I sign my name on a distribution sheet and pay my $3 Medicare co-pay. The government, meaning our tax dollars, pays the other $367 for my medicine.  Now I am ready to go – but not before my ‘synthetic cannabinoid’ dealer informs me of possible side effects. She warns me to be on the lookout for – “dizziness, drowsiness, confusion, feeling ‘high,’ an exaggerated sense of well-being, lightheadedness, headache, red eyes, dry mouth, nausea, vomiting, stomach pain, clumsiness, or unsteadiness.”

Geez – sounds like a lot of potential adversity on my chemically sensitive body.  From personal experience, I know that the herbal cannabinoids do not cause these side effects in my body. The pharmacist did mention one noticeable side effect that I have had with eating cannabis brownies: dry mouth – which is hardly a problem when considering the overall benefits of the medicine.

When I get home I open the bag to take a look at the Marinol. The pills are a deep maroon color and perfectly round. They remind me of Boston Baked Beans – as they look exactly like those candies. One thing is for sure: synthetic cannabinoids do not look anything like herbal cannabinoids – the ones from the plant itself. The distinct medical difference of popping pills versus the variations and qualities of consuming natural cannabis cannot be understated – and surely won’t be by me. After a week of taking one pill a night before bed, as the doctor prescribed, I do not notice any positive effects from the Marinol. It makes me hungry – but that was never a problem in the first place. However, it is my first legal cannabinoid and that is what counts, right? – Not whether it works, just whether it is legal, right?

Wrong.

Here is what I know.  I have been self-medicating with herbal cannabinoids for five years to provide relief from MS, which I have had for 23 years.  During that time I went through the long list of prescribed pharmaceuticals.  The relief was minimal. The problem was (and is) the side effects, which became unbearable over time. I felt like a slave, dependent on a cycle of pharmaceutical use which abused my body and left me in the most depressed, hopeless, and flattened state.

I finally said enough of the pharma-tinkering with my body and the MS and tried baking herbal cannabinoids into brownies. In doing so, my alternative treatment made me a criminal. I began to eat a small cube of cannabis brownie three times a day. Within the first month my insomnia disappeared, my bladder issues calmed, nerve tingles of the arms, legs, and feet stilled. I was no longer breaking out in upper body tremors after being out in the world of loud noises, traffic, and the everyday racing of life.  The MS was quieter. I found I wasn’t contemplating suicide and I felt hopeful about my life again – but realized I had become a chronic criminal.

Cannabinoids are clearly medicinal to our bodies. But there is a strange distinction between which cannabinoids are effective and which ones are legal.  In the case of my MS, appetite stimulation has not been a problem – which is what the Marinol is usually prescribed for. Marinol simply did not work for me. There are other pharmaceutical cannabinoids – such as Nabilone and Sativex – available in other countries, but they remain expensive and less effective than herbal cannabinoids.  Nature created cannabis and the mammalian ECS, not you or me – and it was through the use of herbal cannabinoids that I was able to wean myself from a life of pharma-cocktails and move toward a healthier life. – Just as nature designed.

This is the first chapter of book in progress titled The Cannabis Papers being published by Illinois NORML.

More chapters are available for review here.

*Publius is Bryan Brickner, Julie Falco, Dianna Lynn Meyer, Stephen Young, William Abens, Danielle Schumacher, Derek Rea (1954-2008), David Nott, Dan Linn, Dan S. Wang, Brian Allemana, and many others.

NORML’s Weekly Legislative Update

Lawmakers around the country are debating a record number of marijuana law reform bills in 2010. NORML’s Weekly Legislative Round Up is your one-stop guide to pending marijuana law reform legislation around the country, along with tips for influencing the policies of your state.

** A note to first time readers: NORML can not introduce legislation in your state. Nor can any other non-profit advocacy organization. Only your state representatives, or in some cases an individual constituent (by way of their representative; this is known as introducing legislation ‘by request’) can do so. NORML can — and does — work closely with like-minded politicians and citizens to reform marijuana laws, and lobbies on behalf of these efforts. But ultimately the most effective way — and the only way — to successfully achieve statewide marijuana law reform is for local stakeholders and citizens to become involved in the political process and make the changes they want to see. We can’t do it without you.

California: Democrat Assemblyman Tom Ammiano reintroduced legislation on Thursday that seeks to legalize the production, distribution, and personal use of marijuana for adults age 21 and older. Assembly Bill 2254, the Marijuana Control, Regulation, and Education Act of 2010, would enact regulations governing the commercial production and retail sale of marijuana for adults. The noncommercial cultivation of marijuana for personal use would not be subject to taxation under the proposal. In addition, AB 2254 would not alter existing legislation on the use of medicinal cannabis, nor would it impose new taxes or sanctions on the medical cultivation of cannabis.

In January, a previous version of this proposal (AB 390) was approved by the California Assembly, Committee on Public Safety. The vote was the first time since 1913 that lawmakers had called for the repeal of cannabis prohibition. Further votes on AB 390 did not take place because of calendar restraints. To learn more about AB 2254, please visit NORML’s ‘Take Action Center’ here or go to California NORML’s website here.

Washington: Senate lawmakers failed to act this week on Senate Bill 5615, which sought to reclassify minor marijuana possession offenses from a criminal misdemeanor to a fine-only civil infraction. Their inaction kills the bill for this legislative session.

In January, House lawmakers also rejected a proposal that sought to legalize and regulate marijuana production, sale, and use to those age 21 or older. Yet a January statewide poll of 500 adults found that a solid majority of Washington voters support legalizing marijuana. As a result, NORML Legal Committee member Douglas Hiatt, along with NORML Board Member Jeffrey Steinborn and others are petitioning to place the issue before state voters this November. To qualify for the ballot, organizers needs to turn in 241,153 valid signatures of registered voters to the Secretary of State’s Office on or before July 2. You can learn more about this effort here.

Washington, DC: Members of the DC City Council’s Committee on Health will hold their first hearing on implementing the District’s new medical marijuana law on Tuesday, February 23. Council members will hear testimony regarding B 18-622, the Legalization of Marijuana for Medical Treatment Initiative Amendment Act 0f 2010, which seeks to implement local regulations regarding the medical use and distribution of medical marijuana to qualified patients. Representatives from NORML will be in attendance and testifying on behalf of the measure. You can read NORML’s written testimony to the Committee here. If you wish to attend this hearing, please go here.

New Hampshire: House lawmakers will be spending part of their summer debating the merits of regulating adult marijuana use. In January members of the House Criminal Justice and Public Safety Committee heard testimony in favor of House Bill 1652, which sought to “allow [for] the purchase and use of marijuana by adults.” (Read NORML’s testimony to the Committee here.) On January 27, members of the Committee voted 16-2 on a motion to refer the bill to a special interim study committee. Members of the full House recently affirmed this amendment by a vote of 272 to 76, meaning that the Criminal Justice and Public Safety Committee will study the bill more thoroughly this summer, and it will issue recommendations for the following legislative session by November.

Iowa: On Wednesday, February 17, the Iowa Board of Pharmacy voted unanimously in favor of reclassifying marijuana as a medicine under state law. (Note, this vote does not legalize the medical use of marijuana in Iowa.)

However, despite this latest decision from the Board, as well as a just-released statewide poll indicating that 64 percent of Iowans back legalizing marijuana for medical purposes, news reports indicate that lawmakers are not yet supportive of House File 2179, which seeks to legalize the physician-supervised use of cannabis. If you live in Iowa, please take time to contact your lawmakers here.

For information on additional state and federal marijuana law reform legislation, please visit NORML’s ‘Take Action Center’ here

‘Gold Standard’ Studies Show That Inhaled Marijuana Is Medically Safe And Effective

The results of a series of randomized, placebo-controlled clinical trials assessing the efficacy of inhaled marijuana consistently show that cannabis holds therapeutic value comparable to conventional medications, according to the findings of a 24-page report issued earlier today to the California state legislature by the California Center for Medicinal Cannabis Research (CMCR).

Four of the five placebo-controlled trials demonstrated that marijuana significantly alleviated neuropathy, a difficult to treat type of pain resulting from nerve damage.

“There is good evidence now that cannabinoids (the active compounds in the marijuana plant) may be either an adjunct or a first-line treatment for … neuropathy,” said Dr. Igor Grant, Director of the CMCR, at a news conference at the state Capitol.  He added that the efficacy of smoked marijuana was “very consistent,” and that its pain-relieving effects were “comparable to the better existing treatments” presently available by prescription.

A fifth study showed that smoked cannabis reduced the spasticity associated with multiple sclerosis.  A separate study conducted by the CMCR established that the vaporization of cannabis – a process that heats the substance to a temperature where active cannabinoid vapors form, but below the point of combustion – is a “safe and effective” delivery mode for patients who desire the rapid onset of action associated with inhalation while avoiding the respiratory risks of smoking.

Two additional clinical trials remain ongoing.

The CMCR program was founded in 2000 following an $8.7 million appropriation from the California state legislature.  The studies are some of the first placebo-controlled clinical trials to assess the safety and efficacy of inhaled cannabis as a medicine to take place in over two decades.

Placebo-controlled clinical crossover trials are considered to be the ‘gold standard’ method for assessing the efficacy of drugs under the US FDA-approval process.

“These scientists created an unparalleled program of systematic research, focused on science-based answers rather than political or social beliefs,” said former California Senator John Vasconcellos, who sponsored the legislation in 1999 to launch the CMCR.  Vasconcellos called the studies’ design “state of art,” and suggested that the CMCR’s findings “ought to settle the issue” of whether or not medical marijuana is a safe and effective medical treatment for patients.

“This (report) confirms all of the anecdotal evidence – how lives have been saved and pain has been eased,” said California Democrat Senator Mark Leno at the press conference.  “Now we have the science to prove it.”

Full text of the CMCR’s report to the California legislature is available at online at: http://www.cmcr.ucsd.edu/CMCR_REPORT_FEB17.pdf.

Supposed Marijuana And Schizophrenia Link “Overstated”

[Editor's note: This post is excerpted from this week's forthcoming NORML weekly media advisory. To have NORML's media advisories delivered straight to your in-box, sign up for NORML's free e-zine here.]

Clinical evidence indicating that marijuana use may be casually linked to incidences of schizophrenia or other psychological harms is not compelling, according to a scientific review published online by the journal Addiction.

Investigators at the University of Bristol, Department of Social Medicine assessed the potential health risks of cannabis, particularly whether use of the drug may be causally linked with mental illness.

Authors wrote: “We continue to take the view that the evidence that cannabis use causes schizophrenia is neither very new, nor by normal criteria, particularly compelling. … For example, our recent modeling suggests that we would need to prevent between 3000 and 5000 cases of heavy cannabis use among young men and women to prevent one case of schizophrenia, and that four or five times more young people would need to avoid light cannabis use to prevent a single schizophrenia case. … We conclude that the strongest evidence of a possible causal relation between cannabis use and schizophrenia emerged more than 20 years ago and that the strength of more recent evidence may have been overstated.”

In 2007, an analysis in the British medical journal The Lancet estimated that experimenting with marijuana could increase one’s risk of developing a psychotic illness later in life by some 40 percent. Following this report, Parliament in 2008 voted to reclassify marijuana as a Class B substance, making its possession punishable by up to five years in prison.

University of Bristol researchers also criticized Parliament’s reclassification of the drug, which took effect earlier this year. They concluded: “The only important possible benefit of prohibition is prevention of cannabis use. There is little or no evidence that it effectively achieves this benefit. Patterns of cannabis use in the population appear to be independent of the policy surrounding use, and criminalizing individual cannabis users does not appear to modify their use in a healthy way.”

Overall, investigators determined that marijuana’s most significant health risk was its association and reinforcement with tobacco smoking.

CBS rejects NORML legalization billboard, but accepts “Black Children are an Endangered Species” anti-abortion billboard

This fifteen second Flash animation from NORML touting the economic benefit of marijuana legalization was too objectionable to CBS, who canceled NORML’s contract to place the following on the giant “Super Billboard” in Times Square:

We also noted the hypocrisy of telling us that NORML’s ad was too contentious an issue ad for the billboard while running – on Super Bowl Sunday – the controversial Focus on the Family anti-abortion ad featuring college QB Tim Tebow and his mother:

Now courtesy of Huffington Post we can show you another acceptable advertisement for CBS Billboards in Atlanta:

...but this billboard in Atlanta is perfectly acceptable

It does not matter which side of the abortion debate you lie, you can certainly agree that abortion is one of the most contentious and controversial issues of our times. NORML, Focus on the Family, and the African-American anti-abortion outreach group Life Education and Research Network that funded these latest Atlanta billboards are all non-profit advocacy organizations lobbying for very controversial issues.

However, the anti-abortion groups seem to have no trouble getting their message out on CBS airwaves and billboards, while NORML is denied four times in two years the opportunity to pay to use the same airwaves and billboards.

I also find it interesting that the groups whose messages are accepted by CBS are trying to criminalize a legal activity (abortion), a policy position only supported by 42% of the American people surveyed in the latest Quinnipiac University poll; whereas NORML’s message of legalization rejected by CBS is a policy position supported by 44% to 53% of the American people surveyed lately by Gallup and Angus Reid. Even more interesting when CBS itself polled support for legalization at 41%.

Drug War’s Underbelly Examined By National Public Radio

Kudos to the producers and editors at National Public Radio for the second time in a week for examining parts of the drug war’s underbelly, notably the economics of cannabis under prohibition and the immense problems created in America’s criminal justice system by its over reliance on  informants.

Annually, over $30 billion in local, county, state and federal tax revenues don’t find their way to public tax coffers because the government continues to prohibit rather than tax cannabis-related businesses, products and services. To make matters worse, an estimated $300-$400 million is paid out annually by law enforcement to confidential informants and snitches.

Another Public Broadcast Corporation entity, the long-running documentary series Frontline, performed an important public service when it broadcast Snitch in 1999.

In a free society guided by a constitution that secures numerous rights and privilege to individuals–with checks and balances on government power–the over reliance of snitches by American law enforcement is yet another terrible outgrowth attributable to a 73-year old public policy, cannabis prohibition, that has failed to the point where even greater government atrocities are justified to maintain the failed policy.